A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included trials.

Trial type	First author, year	Patient			Apatinib (mg·d^−1)	Intervention (regimen, cycle, or duration)	Criteria	Outcomes
		Age (years)	No. (E/C)	TP
CCS	Li, 2018 [18]	26–70^a	21/25^d	FSMC	500	E: apatinib + taxane or anthracycline, 6 cycles; C: taxane or anthracycline, 6 cycles	RECIST 1.1, CTCAE	O1, 4
CCS	Cheng et al., 2018 [19]	Un	46/46^d	FSMC	250	E: apatinib + taxanes, 6 cycles; C: taxane, 6 cycles	Un, CTCAE	O1, 4
CCS	Shao et al., 2019 [20]	64.2 ± 1.63/58.55 ± 1.45^b	54/54^d	Un	500	E: apatinib + taxane + platinum, Un; C: taxane + platinum, Un	Un, Un	O1. 4
CCS	Liu et al., 2020 [21]	36.9 ± 5.1/45.1 ± 4.9^b	22/22^d	FSMC	500	E: apatinib + taxanes or anthracycline, Un; C: taxanes or anthracycline, Un	RECIST 1.1, WHO	O1, 4
CCS	Zhang and Shi, 2020 [22]	18–70^a	21/25^d	FPC	500	E: apatinib + gemcitabine, Un; C: gemcitabine, Un	RECIST 1.1, Un	O1, 3, 4
CCS	Zhang and Xiong, 2019 [23]	53.4 ± 4.2/53.3 ± 4.6^b	30/30^d	Un	500	E: apatinib + platinum, 8 cycles; C: platinum, 8 cycles	Un	O4
CCS	Zhao, 2018 [24]	49–75^a	16/20^d	FPC	500	E: apatinib + anthracycline, 6 cycles; C: anthracycline, 6 cycles	RECIST 1.1, Un	O1, 4
RCT	Feng et al., 2019 [25]	45.8 ± 5.7/46.2 ± 6.1^b	30/30^d	FPC	Un	E: apatinib + platinum, 4 cycles; C: platinum, 4 cycles	Un, Un	O1, 4
RCT	Ren, 2019 [26]	74.0 ± 1.3/75.0 ± 1.5^b	38/38^d	FSMC	500	E: apatinib + platinum, Un; C: platinum, Un	WHO, Un	O1, 2, 3, 4
RCT	Wang and Qu, 2019 [27]	50.68 ± 16.84^C	39/39^d	FPC	425	E: apatinib + taxane + platinum, 3 cycles; C: taxane + platinum, 3 cycles	RECIST 1.1, Un	O1, 3, 4
RCT	Liu, 2015 [28]	48.5 ± 5.5/48.0 ± 5.0^b	37/37^d	Un	850	E: apatinib + taxane + platinum, 4 cycles; C: taxane + platinum, 4 cycles	WHO	O4
RCT	Zhao et al., 2019 [29]	54.29 ± 6.87/54.76 ± 6.72^b	19/19^d	FSMC	500	E: apatinib + taxane or anthracycline, Un; C: taxane or anthracycline, Un	Un	O1
RCT	Zheng et al., 2019 [30]	60.5 ± 5.1/60.1 ± 4.9^b	40/40^d	FPC	Un	E: apatinib + taxane + anthracycline, 6–8cycles; C: taxane + anthracycline, 6–8cycles	WHO, Un	O1, 4
RCT	Quan, 2020 [31]	55.89 ± 7.76/55.21 ± 7.71^b	50/50^d	FPC	250	E: apatinib + taxane or anthracycline, Un; C: taxane or anthracycline, Un	Un, Un	O1, 2, 4
RCT	Ran and Liu, 2020 [32]	52.10 ± 12.19/51.37 ± 12.53^b	41/41^d	FFC	500	E: apatinib + gemcitabine, 3 cycles; C: gemcitabine, 3 cycles	RECIST 1.1, CTCAE	O1, 2, 3, 4

Note: CCS: case-control study; RCT: randomized clinical trial; E: experimental group; C: control group; Un: unclear; ^aall patients (range); ^bE/C (mean ± SD); ^Call patients (mean ± SD); ^dthe number of patients in experimental and control groups; TP: treatment process; FFC: failure of first-line chemotherapy; FPC: failure of platinum-based chemotherapy; FSMC: failure of second-line or multiple-line chemotherapy; WHO: World Health Organization guidelines for solid tumor responses, adverse events, and quality of life; RECIST 1.1: Version 1.1 of Response Evaluation Criteria in Solid Tumors; CTCAE: Common Terminology Criteria for Adverse Events; O: outcomes; O1: tumor response including objective response rate and disease control rate; O2: survival status including overall survival, time to progression, and progression-free survival; O3: tumor-associated antigen; and O4: adverse drug reactions.